Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
118actual
Sites
52
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-18 | actual | When the study began enrolling |
| Primary completion | 2026-04-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-27 | actual | The whole study's end, after follow-up |
| First posted | 2021-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson's Disease (PD)
Intervention
- Drug: ABBV-951 — also filed as Foscarbidopa, Foslevodopa
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with Adverse Event (AEs)
measured Up to Week 96
Percentage of Participants with AEs of Special Interest (AESIs)
measured Up to Week 96
Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation Scale
measured Up To Week 96
Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation Scale
measured Up To Week 96
Change From Baseline in Suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
measured Up To Week 96
Change From Baseline in Impulsive-Compulsive Disorders and related behaviors as assessed in Parkinson's Disease- Rating Scale (QUIP-RS)
measured Up To Week 96
Change From Baseline in Cognitive Impairment as Assessed by the Mini-Mental State Examination (MMSE)
measured Up To Week 96
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed.
measured Up to Week 96
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements like Systolic and Diastolic Blood Pressure will be Assessed
measured Up to Week 96
Change From Baseline in Electrocardiograms (ECGs)
measured Up to Week 96
Publications
- PMID 40402298 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed